Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02601209 · ClinicalTrials.gov registry record · Phase 1
Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 151
- Enrollment target
NCT02601209: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT02601209 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 151 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02601209, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 151 participants
- Enrollment target
Study Summary
This phase I/II trial studies the side effects and best dose of sapanisertib and to see how well it works compared to pazopanib hydrochloride in treating patients with sarcoma that is too large to be removed (locally advanced) or has spread to other areas of the body (metastatic). Sapanisertib and pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- DRUG Sapanisertib
- DRUG Pazopanib
- DRUG Pazopanib Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2015-11-30 |
| Est. Completion | 2022-07-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02601209
The ClinicalTrials.gov registry entry for NCT02601209 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sapanisertib is the first listed.
NCT02601209 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02601209 about?
NCT02601209 is a clinical study titled "Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma". This phase I/II trial studies the side effects and best dose of sapanisertib and to see how well it works compared to pazopanib hydrochloride in treating patients with sarcoma that is too large to be removed (locally advanced) or has spread to other areas of the body (metastatic). Sapanisertib and p...
What is the current status of trial NCT02601209?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 151 participants. The study started on 2015-11-30. Estimated completion is 2022-07-11.
What interventions are being tested in trial NCT02601209?
The interventions under investigation include: Sapanisertib (DRUG), Pazopanib (DRUG), Pazopanib Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT02601209?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.